India Continuous Glucose Monitoring Devices Market (2025 - 2033)

Market Size & Trends

The India continuous glucose monitoring devices market size was estimated at USD 138.9 million in 2024 and is projected to reach USD 672.9 million by 2033, growing at a CAGR of 19.1% from 2025 to 2033. A shift toward proactive diabetes management and the adoption of digital health tools are fueling demand. The rising geriatric population and sedentary lifestyles contribute to the disease burden, necessitating the development of advanced monitoring solutions. Furthermore, expanding healthcare infrastructure, the availability of CGM devices through e-commerce and pharmacies, and collaborations between global players and Indian healthcare providers enhance accessibility. Technological advancements such as sensor accuracy, app integration, and data sharing further support market growth across urban and semi-urban areas.

India, a key country in the International Diabetes Federation (IDF) South-East Asia region, is grappling with a growing diabetes crisis. Of the 589 million global diabetes cases, 107 million are in this region. By 2050, the regional number is expected to rise to 185 million. India alone has a staggering 89.8 million adult diabetes cases, with a 10.5% adult prevalence rate among its 947 million adult population.

To raise awareness and promote better care, World Diabetes Day is observed every year on November 14. The 2024 theme, “Breaking Barriers, Bridging Gaps,” emphasizes collaborative action to improve diagnosis, treatment, and equal access to care. It also encourages health systems to address care disparities and foster inclusion.

Diabetes is a chronic disease caused by insufficient insulin production or improper insulin usage, leading to high blood glucose levels. Left uncontrolled, it can damage vital organs and cause severe complications, including heart disease, kidney failure, blindness, and nerve damage. Early symptoms include frequent urination, thirst, fatigue, blurred vision, and unexplained weight loss.

Preventing type 2 diabetes involves healthy lifestyle changes such as regular physical activity, a balanced diet low in sugar and saturated fats, maintaining a healthy weight, and avoiding tobacco. Experts from the IDF School of Diabetes also highlight the increasing role of Continuous Glucose Monitoring (CGM) devices in proactive diabetes management.

CGMs are transforming diabetes care by offering real-time glucose readings and reducing the need for finger-prick tests. In India, three key CGM devices are making notable impact:

• Tracky by DrStore - India’s first Bluetooth-enabled CGM uses a reusable transmitter and a 14-day sensor. Tailored for Indian users, it offers affordability, real-time data, mobile app connectivity, and alerts for glucose spikes or drops.

• Freestyle Libre by Abbott - This popular device offers 14 days of continuous glucose monitoring via a small sensor worn on the upper arm. It provides a comprehensive glucose profile through easy scanning, eliminating routine finger pricks.

• Dexcom G6 - Known globally, this CGM gives readings every five minutes, connects with smartphones, and does not need fingerstick calibrations. It’s widely used by those with Type 1 or insulin-dependent Type 2 diabetes.

In addition, Trinity Biotech is preparing to enter the Indian CGM market in September 2024, through a partnership with Bayer. It plans to launch an in-country study to understand user and provider feedback, which likely to guide the refinement of its next-gen CGM product. This modular, cost-effective biosensor aims to increase CGM accessibility in India, where uptake is still limited but growing. Trinity Biotech’s strategy focuses on affordability and ease of use, aiming to offer advanced diabetes care to a broader segment of the population.

India is witnessing a significant rise in diabetes cases, with over 101 million people currently affected, according to the ICMR-INDIAB study. Continuous Glucose Monitoring (CGM) technology is emerging as a vital solution in managing this growing burden. Experts emphasize that CGMs empower individuals with real-time data, improve glucose control, reduce complications, and enhance quality of life. These insights are supported by healthcare leaders across research, clinical practice, and public health, who advocate for CGM’s role in personalized diabetes care, better comorbidity management, and expanded healthcare accessibility. Their statements reinforce CGM's impact in transforming diabetes outcomes across India.

India’s Continuous Glucose Monitoring (CGM) devices market is evolving rapidly, with both Over-the-Counter (OTC) and prescription-based products gaining traction. While global players such as Abbott, Dexcom, and Medtronic dominate the clinical segment with prescription devices, Indian startups such as DrStore, Ultrahuman, and Actofit are pioneering OTC CGMs for fitness and preventive care. The growing availability of CGMs through e-commerce, pharmacies, and digital health platforms is expanding consumer access. This shift supports not only diabetes management but also proactive wellness tracking. The table below outlines leading companies, their CGM offerings, availability channels, and target users across India’s emerging OTC vs prescription landscape.

The table below compares key players in India’s CGM market based on their device type, availability, and target segments.

Market Concentration & Characteristics

The India Continuous Glucose Monitoring (CGM) devices industry is moderately concentrated, with key players like Abbott, Medtronic, and Dexcom dominating market share through advanced technology and established distribution networks. The industry is characterized by rapid innovation, increasing demand for real-time glucose monitoring, and growing awareness of diabetes management. Local players and startups are emerging, supported by government healthcare initiatives and rising digital health adoption. The market sees frequent product upgrades, strategic partnerships, and expansion into e-commerce channels. High competition, regulatory standards, and pricing sensitivity also define the landscape, making innovation and affordability key to sustained growth and market penetration.

India’s continuous glucose monitoring (CGM) industry is evolving rapidly, marked by innovation such as Ambrosia’s launch of the nation’s first 24x7 real-time glucose and stress monitoring service in April 2025. Building on success in the U.S. and Europe, Ambrosia’s system uses wearable sensors, AI analytics, and remote access to offer continuous health tracking. Addressing India’s high diabetes and stress-related disorder rates, it fills the gap left by traditional intermittent testing and misleading flash sensor claims. Features like meal impact analysis, Dia-Buddy AI, smart alerts, and remote monitoring enhance safety and usability for diabetics, children, professionals, and fitness enthusiasts.

India’s continuous glucose monitoring (CGM) industry is experiencing moderate to high merger and acquisition (M&A) activity, driven by rising demand and digital health integration. Global players like Abbott and Medtronic have expanded through strategic partnerships with Indian firms, while local startups such as BeatO have acquired healthtech companies to strengthen AI and analytics capabilities. Investors show growing interest, with recent deals involving major healthcare and medtech companies targeting diabetes care innovation. These activities reflect increasing consolidation, technology transfer, and ecosystem development, as domestic and international firms seek to tap into India’s large diabetic population and evolving digital health landscape.

Regulations significantly impact India’s continuous glucose monitoring (CGM) devices industry by ensuring safety, quality, and compliance. Under the Medical Device Rules, 2017, CGM devices are classified as high-risk (Class C or D), requiring Central Drugs Standard Control Organization (CDSCO) approval for manufacturing and import. Since October 2023, stricter licensing norms mandate clinical validation, quality assurance protocols, and post-market surveillance. These regulations align India’s standards with global practices, improving product reliability and user trust. However, they also pose challenges for smaller manufacturers due to complex documentation and extended approval timelines, potentially slowing market entry while encouraging innovation and adherence to international norms.

In India’s continuous glucose monitoring (CGM) devices industry, key substitutes include traditional self‑monitoring of blood glucose (SMBG) through finger-prick glucometers, which remain widely used due to lower cost and easier accessibility. Flash glucose monitoring systems, which provide intermittent glucose readings without real-time alerts, also serve as alternatives. For some patients, periodic lab-based tests like HbA1c offer long-term glucose insights but lack immediacy. Emerging digital health tools such as smartphone-integrated optical sensors and insulin pump algorithms present nascent competition, though they’re yet to match CGM accuracy. Despite these options, CGMs are preferred for their real-time trends, automated alerts, and enhanced disease management.

India’s continuous glucose monitoring (CGM) devices industry is expanding beyond major metropolitan areas into Tier-2 and Tier-3 cities, driven by increasing diabetes awareness, improved healthcare access, and rising disposable incomes. Urban regions remain the primary adopters due to better infrastructure and digital literacy. However, growth in smaller towns and semi-urban areas is accelerating, supported by telemedicine, mobile health services, and digital health platforms. Companies are focusing on regional customization, multilingual support, and affordability to penetrate underserved markets. As public and private healthcare investments rise, regional expansion is expected to play a crucial role in driving long-term CGM adoption across India.

Product Insights

The standalone CGM systems segment dominated the market and accounted for the largest revenue share in 2024. These independent devices, worn directly by users, offer real-time glucose tracking without relying on accompanying insulin pumps or additional equipment. Their popularity stems from ease of use, affordability, and accessibility across urban and emerging markets. Users benefit from continuous data, alerts, and insights into glucose trends without needing complex system integrations. As diabetes awareness and self-care expand in India, standalone CGMs are becoming the preferred choice, supported by wider distribution networks, growing physician endorsement, and competitive pricing strategies from leading manufacturers.

The integrated CGM-insulin pump systems segment is projected to experience the fastest growth in India’s CGM devices market over the forecast period. These combined systems deliver continuous glucose monitoring and automated insulin delivery, significantly enhancing diabetes management by reducing manual interventions and minimizing human error. Their advanced features such as real-time adjustments, predictive insulin dosing, and remote monitoring capabilities appeal to patients seeking smarter and more convenient care. As technology becomes more affordable and users become more health-conscious, adoption is rising among tech-savvy consumers and healthcare providers. Regulatory approvals and increasing physician awareness likely to drive market penetration and growth in this segment.

Connectivity Insights

The Bluetooth segment dominated the India CGM devices market in 2024, capturing the largest revenue share due to its widespread integration in modern glucose monitoring systems. Bluetooth-enabled CGMs allow seamless real-time data transmission to smartphones and wearable devices, improving patient engagement and facilitating remote monitoring by healthcare providers. This wireless connectivity supports better diabetes management through timely alerts and data-driven insights. Increased adoption of digital health platforms, rising awareness of connected care, and compatibility with telemedicine services further fueled this segment’s growth. In addition, the reliability, low energy consumption, and user convenience of Bluetooth technology solidified its leading market position.

The NFC (Near Field Communication) segment in India’s CGM devices market is projected to experience the fastest growth during the forecast period due to its enhanced convenience and accessibility. NFC-enabled CGM sensors allow users to easily scan glucose readings via smartphones or dedicated NFC readers without needing Bluetooth connectivity, reducing device complexity and power consumption. This technology supports seamless data syncing with health apps, enabling trend tracking and caregiver monitoring. Its compatibility with popular smartphones promotes wider adoption, especially among tech-savvy consumers. Additionally, NFC integration supports offline functionality and improved security, addressing data privacy concerns, and expanding CGM access to underserved regions.

Indication Insights

The type 1 diabetes segment dominated the India CGM devices market in 2024, accounting for the largest revenue share. T1D is a lifelong autoimmune condition that requires constant glucose monitoring, making CGM devices essential for effective management. India has the highest number of T1D cases globally, with the incidence rising at a rate of 6.7% annually. Early onset and the need for continuous care are driving demand for real-time monitoring solutions. CGM adoption among T1D patients is increasing due to the ability to reduce complications, improve glycemic control, and enhance quality of life through timely data and automated alert

The type 2 diabetes segment is expected to grow at the fastest pace in India’s CGM devices market during the forecast period. India has approximately 77 million adults living with type 2 diabetes and nearly 25 million more at risk due to prediabetes. A major concern is that over half of these individuals remain undiagnosed, increasing the likelihood of severe health complications. Without timely detection and treatment, unmanaged diabetes can lead to cardiovascular risks, including a two- to three-fold higher chance of heart attacks and strokes. Growing awareness and early intervention are driving greater adoption of CGM devices among this population.

Distribution Channel Insights

The pharmacies segment dominated the India CGM devices market in 2024, accounting for the largest revenue share due to their widespread accessibility and established distribution networks across urban and rural areas. Pharmacies offer trusted, point-of-care locations where customers can buy CGM devices without specialized prescriptions or lengthy waits. Their convenient hours and knowledgeable staff make setup and ongoing support more approachable. In addition, pharmacies often bundle devices with promotions or loyalty programs, enhancing affordability. Integration with pharmacy-managed digital health platforms and in-store demonstrations further boosts consumer confidence. Together, these factors position pharmacies as the preferred retail channel for CGM adoption in India.

The e‑commerce segment is poised to achieve the fastest growth in India’s CGM devices market due to several key factors. Firstly, convenient online purchasing allows users especially in remote and semi‑urban areas, to access a wide range of CGM products without relying on local physical stores. Secondly, competitive online pricing, frequent promotions, and bundled deals make CGM devices more affordable. Thirdly, seamless doorstep delivery ensures an uninterrupted supply of sensors and accessories. Lastly, ease of comparing specifications, reading peer reviews, and accessing customer support via digital platforms builds user confidence, driving adoption across diverse demographic segments.

Key India Continuous Glucose Monitoring Devices Company Insights

Leading market players include Abbott and Dexcom, which have strengthened their position in India’s CGM market through innovation and competitive pricing. By focusing on affordability, user-friendliness, and expanded access, they have significantly driven CGM adoption across various channels such as pharmacies, e-commerce, and personal health management, broadening reach and improving diabetes care delivery.

Recent Developments

• In June 2025, Tracky, a healthtech brand by DrStore, launched India’s first Bluetooth-enabled CGM to enhance diabetes care. The device offers real-time, scan-free glucose monitoring via a mobile app, improving affordability and accessibility. Priced at ₹5,999, (USD 72), it supports lifestyle tracking and plans AI integration for personalized health insights and predictive alerts.

• In January 2024, Trinity Biotech signed a non-binding Letter of Intent with Bayer to jointly launch a low-cost CGM biosensor in China and India. The partnership aims to enhance diabetes care access in both countries, leveraging Bayer’s market presence to provide innovative, affordable solutions amid rising diabetes prevalence and growing CGM adoption.

India Continuous Glucose Monitoring Devices Market